Enhancing the circulating half-life of antibody-based fusion proteins

• US 20060034836A1
• Filed: 11/07/2005
• Published: 02/16/2006
• Est. Priority Date: 02/11/2000
• Status: Active Grant

• Current Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Original Assignee: EMD Lexigen Research Center Corp.
• Inventors: Gillies, Stephen D., Lo, Kin-Ming, Burger, Christa
• Granted Patent: US 7,507,406 B2
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6813 the drug being a peptidic cytokine, e.g. an interleukin or interferon
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: C07K 14/525 Tumour necrosis factor [TNF]
• CPC Class Codes: C07K 14/55 IL-2
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 5/1013 the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Abstract

Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.

Claims

1. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein the C-terminal non-Ig protein comprising an amino acid substitution introducing a hydrophobic or non-polar amino acid within 10 amino acids of the N-terminus of the C-terminal non-Ig protein, wherein said antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without said amino acid substitution.

13. The method of claim 1, wherein said non-Ig protein is selected from the group consisting of a cytokine, a ligand-binding protein, and a protein toxin.

16. The method of claim 1, wherein said non-Ig protein is interleukin-2.

29. The method of claim 1, wherein the Ig chain comprises

(i) a deletion of a charged amino acid within 10 amino acids of the C-terminus of the Ig chain, or

(ii) an amino acid alteration introducing a hydrophobic or non-polar amino acid within 10 amino acids of the C-terminus of the Ig chain.

3. (canceled)

5-6. -6. (canceled)

8-10. -10. (canceled)

12. (canceled)

14-15. -15. (canceled)

17-23. -23. (canceled)

25-28. -28. (canceled)

30-35. -35. (canceled)

37-45. -45. (canceled)

48. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising an IgG2, IgG3, IgG4, IgA, IgM, IgD, or IgE domain and an amino acid substitution introducing a hydrophobic or non-polar amino acid within 10 amino acids from the C-terminus of the Ig chain, wherein the antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.

2. The method of claim 48 wherein the amino acid substitution increases the hydrophobicity of said antibody-based fusion protein.

4. The method of claim 48 wherein said substitution changes the C-terminal amino acid of the Ig chain.

7. The method of claim 48, wherein the Ig chain comprises part of an Ig heavy chain.

11. The method of claim 7, wherein said part of an Ig heavy chain has binding affinity for an immunoglobulin protection receptor.

24. The method of claim 48 comprising a linker between said Ig chain and said non-Ig protein.

36. The method of claim 4 wherein the substitution introduces an amino acid with a non-ionizable side chain.

46. The method of claim 48, wherein said hydrophobic or non-polar amino acid is selected from the group consisting of Leu, Ala, Trp, and Gly.

47. The method of claim 46, wherein said hydrophobic or non-polar amino acid is Ala.

49. The method of claim 48 wherein the constant domain comprises at least one of a CH1, CH2, or CH3 domain.

50. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising:

at least one of a CH2 and CH3 domain; and

an amino acid sequence that is non-natural within 10 amino acids from its C-terminus, the non-natural amino acid sequence comprising an amino acid substitution introducing a hydrophobic or non-polar amino acid, wherein the antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.

51. The method of claim 50, wherein the Ig chain is an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgD, or IgE chain.

52. The method of claim 51 wherein the Ig chain comprises the CH2 domain of the IgG2 constant region and a C-terminal lysine is substituted with a nonpolar or hydrophobic amino acid.

53. The method of claim 52, wherein the C-terminal lysine is substituted with an alanine.

54. The method of claim 52, wherein the non-Ig protein is a cytokine.

55. A method for treating a disease, the method comprising the step of administering to a patient an antibody-based fusion protein comprising an N-terminal immunoglobulin (Ig) chain linked to a C-terminal non-Ig protein, the Ig chain comprising an amino acid substitution within 10 amino acids from the C-terminus, the substitution replacing a charged amino acid with a hydrophobic or non-polar amino acid, wherein the antibody-based fusion protein has a longer circulating half-life in vivo than a corresponding antibody-based fusion protein without the amino acid substitution.

56. The method of claim 55, wherein the hydrophobic or non-polar amino acid is selected from the group consisting of Ala, Gly and Trp.